Patents by Inventor Avital Laxer

Avital Laxer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250243242
    Abstract: The disclosure is in part directed to crystalline forms of ((S)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl)-A-tyrosine and pharmaceutical compositions thereof.
    Type: Application
    Filed: March 16, 2023
    Publication date: July 31, 2025
    Inventors: Avital Laxer, Elana Gazal, Alaa Talhami
  • Publication number: 20240207410
    Abstract: Disclosed herein are levodopa prodrug compounds and methods for their use. Further disclosed herein are liquid pharmaceutical formulations comprising a levodopa-tyrosine conjugate and a stabilizer, wherein the liquid pharmaceutical formulations may further comprise a decarboxylase inhibitor, such as carbidopa, an antioxidant, a solvent, or any other pharmaceutically acceptable excipient. Further disclosed are methods of treating generative conditions and/or conditions characterized by reduced levels of dopamine in the brain, such as Parkinson's disease, comprising administering the disclosed prodrugs and/or liquid pharmaceutical formulations.
    Type: Application
    Filed: March 9, 2022
    Publication date: June 27, 2024
    Inventors: Avital Laxer, Elana Gazal, Mazzi Dagan-Lion, Irena Vainshtok, Alaa Talhami, Alex Mainfield, Eduardo Zawoznik, Kenji Morokuma, Kazuki Nakayama, Eiji Yoshida, Akira Nakao
  • Publication number: 20170327464
    Abstract: The subject invention provides a mixture of crystalline laquinimod sodium particles, wherein (i) 90% or more of the total amount by volume of the laquinimod sodium particles have a size of 40 microns or less or (ii) 50% or more of the total amount by volume of the laquinimod sodium particles have a size of 15 microns or less, and wherein: a) the mixture has a bulk density of 0.2 g/mL to 0.4 g/mL; b) the mixture has a tapped density of 0.40 g/mL to 0.7 g/mL; c) an amount of heavy metal in the mixture is no more than 0.002% of heavy metal relative to the amount by weight of laquinimod sodium; d) an amount of 5-chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline (MCQ) in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; e) an amount of 5-chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid (MCQCA) in the mixture is no more than 0.
    Type: Application
    Filed: August 1, 2017
    Publication date: November 16, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Anton Frenkel, Avital Laxer
  • Publication number: 20170065576
    Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.
    Type: Application
    Filed: November 17, 2016
    Publication date: March 9, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
  • Publication number: 20160158216
    Abstract: The subject invention provides a mixture of crystalline laquinimod sodium particles, wherein (i) 90% or more of the total amount by volume of the laquinimod sodium particles have a size of 40 microns or less or (ii) 50% or more of the total amount by volume of the laquinimod sodium particle have a size of 15 microns or less, and wherein: a) the mixture has a bulk density of 0.2 g/mL to 0.4 g/mL; b) the mixture has a tapped density of 0.40 g/mL to 0.7 g/mL; c) an amount of heavy metal in the mixture is no more than 0.002% of heavy metal relative to the amount by weight of laquinimod sodium; d) an amount of 5-chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline (MCQ) in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; e) an amount of 5-chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid (MCQCA) in the mixture is no more than 0.
    Type: Application
    Filed: December 3, 2015
    Publication date: June 9, 2016
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Anton Frenkel, Avital Laxer
  • Publication number: 20160151345
    Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.
    Type: Application
    Filed: February 2, 2016
    Publication date: June 2, 2016
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
  • Publication number: 20160151346
    Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.
    Type: Application
    Filed: February 2, 2016
    Publication date: June 2, 2016
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
  • Patent number: 9284276
    Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: March 15, 2016
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
  • Patent number: 9233927
    Abstract: The subject invention provides a mixture of crystalline laquinimod sodium particles, wherein (i) 90% or more of the total amount by volume of the laquinimod sodium particles have a size of 40 microns or less or (ii) 50% or more of the total amount by volume of the laquinimod sodium particles have a size of 15 microns or less, and wherein: a) the mixture has a bulk density of 0.2 g/mL to 0.4 g/mL; b) the mixture has a tapped density of 0.40 g/mL to 0.7 g/mL; c) an amount of heavy metal in the mixture is no more than 0.002% of heavy metal relative to the amount by weight of laquinimod sodium; d) an amount of 5-chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline (MCQ) in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; e) an amount of 5-chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydroqunoline-3-carboxylic acid (MCQCA) in the mixture is no more than 0.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 12, 2016
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Anton Frenkel, Avital Laxer
  • Patent number: 9102620
    Abstract: The subject invention provides deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, its salts and uses.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 11, 2015
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Victor Piryatinsky, Avital Laxer
  • Patent number: 8975279
    Abstract: The subject invention provides a Laquinimod amine salt, which is laquinimod meglumine, laquinimod choline hydroxide, laquinimod L-lysine or laquinimod monoethanolamine.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 10, 2015
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Anton Frenkel, Avital Laxer, Judith Aronheim
  • Publication number: 20140343096
    Abstract: The subject invention provides deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, its salts and uses.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 20, 2014
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Victor Piryatinsky, Avital Laxer
  • Publication number: 20140271878
    Abstract: The subject invention provides a mixture of crystalline laquinimod sodium particles, wherein (i) 90% or more of the total amount by volume of the laquinimod sodium particles have a size of 40 microns or less or (ii) 50% or more of the total amount by volume of the laquinimod sodium particles have a size of 15 microns or less, and wherein: a) the mixture has a bulk density of 0.2 g/mL to 0.4 g/mL; b) the mixture has a tapped density of 0.40 g/mL to 0.7 g/mL; c) an amount of heavy metal in the mixture is no more than 0.002% of heavy metal relative to the amount by weight of laquinimod sodium; d) an amount of 5-chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline (MCQ) in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; e) an amount of 5-chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydroqunoline-3-carboxylic acid (MCQCA) in the mixture is no more than 0.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Anton Frenkel, Avital Laxer
  • Patent number: 8809537
    Abstract: The subject invention provides pharmaceutical compositions containing laquinimod or a pharmaceutically acceptable salt thereof, an isolated compound of N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide or a salt thereof, compositions containing N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide and methods of preparing the same.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: August 19, 2014
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Avital Laxer, Konstantin Ulanenko
  • Publication number: 20140171647
    Abstract: Disclosed is a process for the preparation of laquinimod sodium which removes the impurities after the salt formation step, thus resulting in crystals of higher purity as well as crystals having improved crystalline characteristics.
    Type: Application
    Filed: February 20, 2014
    Publication date: June 19, 2014
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Anton Frenkel, Eduard Gurevich, Avital Laxer
  • Publication number: 20140128430
    Abstract: The subject invention provides a Laquinimod amine salt, which is laquinimod meglumine, laquinimod choline hydroxide, laquinimod L-lysine or laquinimod monoethanolamine.
    Type: Application
    Filed: October 31, 2013
    Publication date: May 8, 2014
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Anton Frenkel, Avital Laxer, Judith Aronheim
  • Patent number: 8673322
    Abstract: Disclosed is a process for the preparation of laquinimod sodium which removes the impurities after the salt formation step, thus resulting in crystals of higher purity as well as crystals having improved crystalline characteristics.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: March 18, 2014
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Anton Frenkel, Eduard Gurevich, Avital Laxer
  • Publication number: 20140051723
    Abstract: The subject invention provides deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, its salts and uses.
    Type: Application
    Filed: October 24, 2013
    Publication date: February 20, 2014
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Victor Piryatinsky, Avital Laxer
  • Patent number: 8647646
    Abstract: Disclosed is a process for the preparation of laguinimod sodium which removes the impurities after the salt formation step, thus resulting in crystals of higher purity as well as crystals having improved crystalline characteristics.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: February 11, 2014
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Anton Frenkel, Eduard Gurevich, Avital Laxer
  • Publication number: 20130345256
    Abstract: The subject invention provides pharmaceutical compositions containing laquinimod or a pharmaceutically acceptable salt thereof, an isolated compound of N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide or a salt thereof, compositions containing N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide and methods of preparing the same.
    Type: Application
    Filed: May 7, 2013
    Publication date: December 26, 2013
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Avital Laxer, Konstantin Ulanenko